Open Access
Short Note
Issue
Parasite
Volume 25, 2018
Article Number 33
Number of page(s) 2
DOI https://doi.org/10.1051/parasite/2018039
Published online 16 July 2018
  1. Chosidow O. 2006. Clinical practices. Scabies. New England Journal of Medicine, 354, 1718–1727. [CrossRef] [Google Scholar]
  2. Chosidow O, Brue C, Chastang C, Bouvet E, Izri M, Rousset J, Monteny N, Bastuji-Garin S, Revuz J. 1994. Controlled study of malathion and d-phenothrin lotions for Pediculus humanus var capitis-infested schoolchildren. Lancet, 344 (8939–890), 1724–1727. [CrossRef] [PubMed] [Google Scholar]
  3. Chosidow O, Fuller LC. 2017. Scratching the itch: Is scabies a truly neglected disease? Lancet Infectious Diseases, 17, 1220–1221. [CrossRef] [Google Scholar]
  4. Chosidow O, Giraudeau B, Cottrell J, Izri A, Hofmann R, Mann SG, Burgess I. 2010. Oral ivermectin versus malathion lotion for difficult-to-treat head lice. New England Journal of Medicine, 362 (10), 896–905. [CrossRef] [PubMed] [Google Scholar]
  5. Currie BJ, McCarthy JS. 2010. Permethrin and ivermectin for scabies. New England Journal of Medicine, 362, 717–725. [CrossRef] [PubMed] [Google Scholar]
  6. Glaziou P, Nyguyen L, Moulia-Pelat J, Cartel J, Martin P. 1994. Efficacy of ivermectin for the treatment of head lice (Pediculosis capitis). Tropical Medicine and Parasitology, 45 (3), 253–254. [Google Scholar]
  7. Karimkhani C, Colombara DV, Drucker AM, Norton SA, Hay R, Engelman D, Steer A, Whitfeld M, Naghavi M, Dellavalle RP. 2017. The global burden of scabies: a cross-sectional analysis from the Global Burden of Disease Study 2015. Lancet Infectious Diseases, 17 (12), 1247–1254. [CrossRef] [Google Scholar]
  8. Lee SH, Yoon K-S, Williamson MS, Goodson SJ, Takano-Lee M, Edman JD, Devonshire AL, Clark JM. 2000. Molecular analysis of kdr-like resistance in permethrin-resistant strains of head lice, Pediculus capitis. Pesticide Biochemistry and Physiology, 66 (2), 130–143. [CrossRef] [Google Scholar]
  9. Muñoz J, Ballester MR, Antonijoan RM, Gich I, Rodríguez M, Colli E, Gold S, Krolewiecki AJ. 2018. Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18 mg tablet in healthy adult volunteers. PLoS Neglected Tropical Diseases, 12 (1), e0006020. [CrossRef] [PubMed] [Google Scholar]
  10. Romani L, Whitfeld MJ, Koroivueta J, Kama M, Wand H, Tikoduadua L, Tuicakau M, Koroi A, Andrews R, Kaldor JM. 2015. Mass drug administration for scabies control in a population with endemic disease. New England Journal of Medicine, 373 (24), 2305–2313. [CrossRef] [Google Scholar]
  11. Rosumeck S, Nast A, Dressler C. 2018. Ivermectin and permethrin for treating scabies. Cochrane Database of Systematic Reviews, 4, CD012994–CD012994. [Google Scholar]
  12. Smit MR, Ochomo EO, Aljayyoussi G, Kwambai TK, Abong’o BO, Chen T, Bousema T, Slater HC, Waterhouse D, Bayoh NM, Gimnig JE, Samuels AM, Desai MR, Phillips-Howard PA, Kariuki SK, Wang D, Ward SA, ter Kuile FO. 2018. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, 18 (6), 615–626. [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.